Validating a New Therapeutic Opportunity for the Treatment of Alzheimer’s Disease

验证治疗阿尔茨海默病的新治疗机会

• 批准号: 133051
• 金额: $ 17.38万
• 依托单位: SENTINEL ONCOLOGY LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133051
• 关键词: Validating; New; Therapeutic; Opportunity; Treatment

There are no effective treatments for Alzheimer’s disease. The incidence and health care costs of treating dementia are set to increase in the coming decades and there is an overwhelming need for effective treatments. Sentinel Oncology Limited (SOL) has developed a new class of drug molecules that have the potential to treat Alzheimer’s Disease. These new drugs would work by preventing the production and activation of proteins in the brain that are involved with the progression of the disease. The purpose of this project is to carry out proof-of-concept experiments to confirm if the SOL drugs have the potential to treat patients with Alzheimer’s Disease.

目前还没有有效的治疗阿尔茨海默病的方法。治疗痴呆症的发病率和医疗保健成本将在未来几十年内增加，并且对有效治疗的需求压倒性地增加。Sentinel Oncology Limited（SOL）开发了一类新的药物分子，具有治疗阿尔茨海默病的潜力。这些新药将通过阻止大脑中与疾病进展有关的蛋白质的产生和激活来发挥作用。该项目的目的是进行概念验证实验，以确认SOL药物是否具有治疗阿尔茨海默病患者的潜力。